George Hill: Good evening, guys and thanks for taking my question. I guess, Yemi and Andrew, I’d start off with how would you guys characterize your visibility to the long-term guide? And I guess, do you think of it as a one end of the spectrum is conservative, the other end of the spectrum is aspirational? And kind of I’d be interested in your comments on the thoughts of putting it €“ just in general, putting it out there, given the uncertainty of the environment that we’re in.
Andrew Dudum: Yes. Thanks, George for the question. I would characterize it as reflective of what we think is reasonable for the business to achieve given the current trajectory of what we see today. And so, I think we intentionally put out there that we think this is €“ a revenue number of at least 1.2 billion and an adjusted EBITDA number of at least 100 million. So, do think that the business can achieve this. We think that, hopefully, the business can surpass it. But it’s fairly representative of the growth we see under the hood today and I think also representative of the, really robust innovation pipeline that we have in the works, both for this year and next year on the proprietary product side across categories and new categories that we think are going to unlock quite a lot of new customer segments and also drive engagement and retention pretty powerfully.
And so, maybe that’s a little bit of color to . I don’t know, Yemi, if there’s anything you’d like to add?
Yemi Okupe: Yes. No. Nothing further from my end.
George Hill: Okay. And then if I could hop in with a follow-up on the new men’s product that you guys launched. I know that you talked about the gross margin erosion over the next couple of years as we look out to 2025, if we compare the Mints product to what I would call like the standard generic ED product, is that product gross margin accretive or dilutive? And I guess, can you talk about €“ do you see a lot of opportunities in other product categories to use formulation as a way to, kind of drive pricing maybe gross margin expansion?
Yemi Okupe: I’ll take the first part of that question and maybe hand it over to Andrew to take the second part. I think over time, we do expect that we have the ability to achieve similar gross margins on the personalized products that we do for more of the generic based products. The gross margin dynamics that we talked about were really just around having line of sight into the flexibility to offer consumers more and more capabilities onto the platform. And so, I think as we look at around how things are likely to evolve, really just having that flexibility is where we see the €“ some of the gross margin dynamics that we referenced earlier come from.
Andrew Dudum: Yes. And to your question, George, about formulation opportunities. I think the answer is absolutely. This, I think, was key to the large strategic purchase of Apostrophe and that compounding infrastructure in pharmacy a couple of years ago. We have always believed that personalized medicine will deliver much better outcomes for patients. And that could be in way of form factor preference. It could be in the way of optimizing side effects by improving different dose dynamics or it could be in the way of optimizing clinical outcomes through different formulation combinations where it makes sense. And so, I think giving the providers on our platform and the patients on our platform increased capabilities to optimize personalized solutions for them, and that means formulation and form factor in a lot of situations across the businesses we’re in and across the future businesses we’re going to launch into is a huge opportunity.
And again, I think this just really reinforces a lot of the investments we’ve been making across the stack to improve the customer experience in such a way where patients really can come to us and know that not only are they going to get the best clinical care, but they’re also going to get products and services that are truly proprietary and unique to our platform and unavailable at other places in market.
